Elite 50% OFF Act now – get top investing tools

00

Days

00

Hours

00

Mins

00

Sec

Register Now!

Lexeo Therapeutics

Contributing Author

Recent Articles by Lexeo Therapeutics

Nov-05	Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
Oct-20	Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering LXEO GlobeNewswire
Oct-16	Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement LXEO GlobeNewswire
Oct-16	Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants LXEO GlobeNewswire
Oct-07	Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy LXEO GlobeNewswire
Aug-14	Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
Jul-07	Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia LXEO GlobeNewswire
Jun-24	Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics LXEO GlobeNewswire
May-27	Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases LXEO GlobeNewswire
May-12	Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
May-01	Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting LXEO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.